aldosterone and Cardiac Remodeling, Ventricular studies

Research Excerpts

Excerpt	Relevance	Reference
"Angiotensin II receptor blockers (ARBs) have been widely used to treat hypertension and large-scale clinical studies have shown various benefits."	9.22	Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). ( Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H, 2016)
"Angiotensin II receptor blockers (ARB) are now commonly used to treat hypertension because of their beneficial effects on cardiovascular remodeling."	9.12	Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006)
"We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)."	9.09	Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001)
"Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis."	7.85	Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017)
" We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)."	7.83	Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016)
"The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood."	7.80	Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014)
"Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies."	7.73	Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006)
"Oral administration of spironolactone improves cardiac remodeling and its central infusion prevents the increase in sympathetic drive post-myocardial infarction (MI)."	7.72	Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. ( Lal, A; Leenen, FH; Veinot, JP, 2004)
"Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)."	7.72	Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004)
"Right ventricular dysfunction was documented in 20 patients."	6.80	Usefulness of Speckle-Tracking Imaging for Right Ventricular Assessment after Acute Myocardial Infarction: A Magnetic Resonance Imaging/Echocardiographic Comparison within the Relation between Aldosterone and Cardiac Remodeling after Myocardial Infarction ( Beaumont, M; Girerd, N; Huttin, O; Juillière, Y; Lemarié, J; Lemoine, S; Mandry, D; Marie, PY; Moulin, F; Selton-Suty, C, 2015)
"Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months."	6.73	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007)
"Aldosterone is an important mediator of the renin-angiotensin-aldosterone system (RAAS) that plays a major role in the pathophysiology of cardiovascular disease as well as regulation of extracellular fluid volume and potassium."	6.43	Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. ( Cohn, JN; Colucci, W, 2006)
"Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass."	6.42	The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004)
"AVP may promote ventricular remodeling."	5.42	The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure. ( Chen, X; Gao, X; Li, Q; Lu, G; Tang, K, 2015)
"CHF was characterized by left ventricular remodeling and impaired systolic and diastolic function."	5.35	Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2008)
"Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI."	5.33	Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005)
"Aldosterone promotes collagen synthesis and structural remodeling of the heart."	5.32	Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. ( Colucci, WS; Kerstetter, DL; Ooi, H; Sam, F; Singh, K; Singh, M; Xie, Z, 2004)
"Angiotensin II receptor blockers (ARBs) have been widely used to treat hypertension and large-scale clinical studies have shown various benefits."	5.22	Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). ( Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H, 2016)
"Angiotensin II receptor blockers (ARB) are now commonly used to treat hypertension because of their beneficial effects on cardiovascular remodeling."	5.12	Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006)
"We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)."	5.09	Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001)
" The selective aldosterone blocker, eplerenone (Inspra), is under development for human therapeutic use for treatment of hypertension and heart failure post-myocardial infarction (MI)."	4.82	Aldosterone target organ protection by eplerenone. ( McMahon, EG; Rocha, R; Rudolph, AE, 2004)
"Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis."	3.85	Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017)
" We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)."	3.83	Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016)
"The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood."	3.80	Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014)
" We evaluated the efficacy of MR antagonism by spironolactone in two experimental PH models; mouse chronic hypoxia-induced PH (prevention model) and rat monocrotaline-induced PH (prevention and treatment models)."	3.79	Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. ( Fanburg, BL; Hill, NS; Jaffe, IZ; Preston, IR; Sagliani, KD; Warburton, RR, 2013)
" We analysed the effects of early chronic VPI (50 mg/kg/day Omapatrilat) on cardiac remodelling and neurohumoral function during the progression of rapid ventricular pacing-induced heart failure in rabbits (early left ventricular dysfunction [ELVD]: 10 days at 330 bpm, CHF: further 10 days at 360 bpm)."	3.78	Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. ( Birner, C; Bratfisch, M; Dietl, A; Götz, T; Luchner, A; Riegger, GA; Schweda, F; Ulucan, C, 2012)
"Hyperhomocysteinemia, neurohormonal activation, inflammation and altered fibrinolysis have been linked to atherothrombosis as well as to myocardial fibrosis and heart failure."	3.75	Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. ( Benjamin, EJ; D'Agostino, RB; Hayes, L; Jacques, P; Joseph, J; Levy, D; Pencina, MJ; Selhub, J; Tofler, GH; Vasan, RS; Wang, TJ, 2009)
"We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination."	3.74	Relations of biomarkers representing distinct biological pathways to left ventricular geometry. ( Aragam, J; Benjamin, EJ; Gona, P; Larson, MG; Levy, D; Lieb, W; Tofler, GH; Vasan, RS; Velagaleti, RS; Wang, TJ, 2008)
"Spironolactone attenuated the myocardial remodelling in Chagas cardiomyopathy, reduced mortality during the chronic phase and reduced inflammatory infiltration."	3.73	Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. ( Billate, A; Fernandes, F; Ianni, BM; Mady, C; Martins, DG; Neto, EC; Ramires, FJ; Salemi, VM, 2006)
"Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies."	3.73	Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006)
"Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)."	3.72	Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004)
"Oral administration of spironolactone improves cardiac remodeling and its central infusion prevents the increase in sympathetic drive post-myocardial infarction (MI)."	3.72	Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. ( Lal, A; Leenen, FH; Veinot, JP, 2004)
"In 43 untreated patients with hypertension with electrocardiographic left ventricular hypertrophy, we measured relative wall thickness and left ventricular mass index by echocardiography and by magnetic resonance imaging (n = 32), intima-media cross-sectional area, and distensibility of the common carotid arteries by ultrasound, media/lumen ratio of isolated subcutaneous resistance arteries by myography, and median 24-hour systolic BP (n = 40), serum insulin, and plasma levels of epinephrine, norepinephrine, renin, angiotensin II, aldosterone, and endothelin."	3.71	Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. ( Devereux, RB; Dige-Petersen, H; Frandsen, E; Hermann, KL; Ibsen, H; Olsen, MH; Rokkedal, J; Wachtell, K, 2002)
"Right ventricular dysfunction was documented in 20 patients."	2.80	Usefulness of Speckle-Tracking Imaging for Right Ventricular Assessment after Acute Myocardial Infarction: A Magnetic Resonance Imaging/Echocardiographic Comparison within the Relation between Aldosterone and Cardiac Remodeling after Myocardial Infarction ( Beaumont, M; Girerd, N; Huttin, O; Juillière, Y; Lemarié, J; Lemoine, S; Mandry, D; Marie, PY; Moulin, F; Selton-Suty, C, 2015)
"Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months."	2.73	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007)
"Primary aldosteronism (PA) is a common cause of secondary hypertension and is associated with worse cardiovascular outcomes."	2.72	Left ventricular remodeling and dysfunction in primary aldosteronism. ( Chang, YY; Chen, ZW; Hung, CS; Lin, YH; Pan, CT; Tsai, CH; Wu, VC, 2021)
"Mycophenolic acid was detected in all cats."	2.61	( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"19."	2.53	Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. ( Bomback, AS, 2016)
"Fibrosis is a fundamental component of the adverse structural remodeling of myocardium present in the failing heart."	2.47	Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. ( Ahokas, RA; Bhattacharya, SK; Gandhi, MS; Gerling, IC; Kamalov, G; Shahbaz, AU; Sun, Y; Weber, KT, 2011)
"Aldosterone is an important mediator of the renin-angiotensin-aldosterone system (RAAS) that plays a major role in the pathophysiology of cardiovascular disease as well as regulation of extracellular fluid volume and potassium."	2.43	Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. ( Cohn, JN; Colucci, W, 2006)
"Heart failure is a major health problem of epidemic proportions."	2.42	Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. ( Ahokas, RA; Gerling, IC; Guntaka, RV; Kiani, MF; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT, 2003)
"Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass."	2.42	The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004)
"Beneficial effects of anti-aldosterone treatment in heart failure may thus be secondary in part to blockade of cardiac aldosterone action."	2.42	Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects. ( Ambroisine, ML; Bendall, JK; Delcayre, C; Fuchs, S; Garnier, A; Heymes, C; Milliez, P; Nehme, J; Robidel, E; Swynghedauw, B, 2004)
"Aldosterone promotes sodium and water retention, sympathoadrenergic activation, endothelial dysfunction, and cardiovascular fibrosis and hypertrophy."	2.42	Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. ( Bauersachs, J; Fraccarollo, D; Galuppo, P, 2004)
"Aldosterone production plays an important role in the remodeling of the heart."	2.41	Molecular mechanisms of myocardial remodeling. The role of aldosterone. ( Delcayre, C; Swynghedauw, B, 2002)
"The elevated aldosterone in primary aldosteronism (PA) is associated with increased insulin resistance and prevalence of diabetes mellitus (DM)."	1.91	Diabetes mellitus is associated with more adverse non-hemodynamic left ventricular remodeling and less recovery in patients with primary aldosteronism. ( Chang, CC; Chang, YR; Chang, YY; Chen, UL; Chueh, JS; Huang, KH; Hung, CS; Lai, TS; Lee, BC; Liao, CW; Lin, YH; Lu, CC; Tsai, CH; Wang, SM; Wu, VC, 2023)
"Patients with primary aldosteronism (PA) have cardiac remodeling due to hemodynamic and non-hemodynamic causes."	1.62	Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism. ( Chang, CC; Chang, YR; Chang, YY; Chen, YL; Chen, ZW; Hung, CS; Lee, BC; Liao, CW; Lin, LC; Lin, YH; Pan, CT; Tsai, CH; Wu, XM, 2021)
"Aldosterone is a key factor in adverse cardiovascular remodeling by acting on the mineralocorticoid receptor (MR) in different cell types."	1.51	Endothelial cell mineralocorticoid receptors oppose VEGF-induced gene expression and angiogenesis. ( Bode, C; Deng, L; Esser, JS; Fürst, D; Hein, L; Huck, M; Kowalski, J; Lother, A; Moser, M, 2019)
"Primary and secondary hyperaldosteronism correlate with LV enlargement and high prevalence of LV hypertrophy and diastolic dysfunction; a subclinical systolic dysfunction is evident only in PA."	1.43	Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study. ( Angeli, P; Cesari, M; Letizia, C; Rosi, S; Rossi, GP; Sciomer, S, 2016)
"A rat model of ventricular remodeling after myocardial infarction was established by left coronary artery ligation."	1.42	Cardioprotective effect of polydatin on ventricular remodeling after myocardial infarction in coronary artery ligation rats. ( Chen, C; Gao, J; Gao, Y; Guo, J; Wang, H; Wu, R, 2015)
"AVP may promote ventricular remodeling."	1.42	The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure. ( Chen, X; Gao, X; Li, Q; Lu, G; Tang, K, 2015)
"From 257 consecutive primary aldosteronism patients, we identified 176 who had both a diagnosis of APA by the 'four corners' criteria and high-quality echocardiographic data."	1.40	KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. ( Cesari, M; Cicala, MV; Iacobone, M; Kuppusamy, M; Letizia, C; Mantero, F; Mareso, S; Pessina, AC; Rossi, GP; Sciomer, S; Seccia, TM; Zinnamosca, L, 2014)
"Hypertension is accompanied by high or low circulating AngII levels and cardiac/renal injury."	1.40	Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension. ( Chen, Y; Liu, C; Liu, H; Meng, W; Sun, Y; Zhao, T; Zhao, W, 2014)
"To examine the effects of houttuynin on ventricular remodeling induced by coronary artery ligation in rats and the underlying mechanisms."	1.40	Beneficial effects of houttuynin on ventricular remodeling induced by coronary artery ligation in rats. ( Chen, CX; Gao, JP; Gao, Y; Guo, J; Wang, HL; Wu, R, 2014)
"Rhodiola Sacra may prevent left ventricular remodeling in SHRs, which is probably attributed to blood pressure lowering and inhibition of RAS, especially myocardial RAS."	1.39	[Effect of Rhodiola Sacra on left ventricular remodeling and its mechanism in spontaneously hypertensive rats]. ( Chen, XP; Liu, K; Yang, R, 2013)
" Chronic administration of a subdepressor dose of eplerenone prevented MR translocation, macrophage infiltration, myocardial fibrosis, cardiac hypertrophy, and LV dysfunction, while not affecting BPV."	1.39	Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats. ( Anegawa, T; Hirooka, Y; Imaizumi, T; Kage, M; Kai, H; Kajimoto, H; Koga, M; Kudo, H; Mifune, H; Miyamoto, T; Takayama, N; Yasuoka, S, 2013)
"Hypertension is characterized by left ventricular (LV) hypertrophy (LVH)."	1.38	Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. ( Baid, S; Garcia, AG; Heo, J; Murthy, NR; Ouchi, N; Sam, F; Wilson, RM, 2012)
"In conclusion, in experimental hyperaldosteronism, the increase in CT-1 expression was associated with parameters showing LVH and fibrosis."	1.37	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. ( Cachofeiro, V; Díez, J; Fortuno, MA; Lahera, V; López-Andrés, N; Martin-Fernandez, B; Rossignol, P; Zannad, F, 2011)
"The ventricular remodeling of mice were induced by subcutaneous injection of ISO with the dosage of 2 mg/kg daily for 7 d and the rats with L-Thy intraperitoneally with the dosage of 0."	1.36	[Effect of Chrysanthemum indicum on ventricular remodeling in rats]. ( Chen, CX; Gao, JP; Gu, WL; Lv, J; Wan, Y; Wu, Q, 2010)
"Ventricular remodeling is an independent risk factor for many cardiovascular events."	1.36	Effect of sodium houttuyfonate on inhibiting ventricular remodeling induced by abdominal aortic banding in rats. ( Chen, CX; Gao, JP; Gu, WL; Li, X; Wu, Q, 2010)
"The evidence is compelling for a role of inflammation in cardiovascular diseases; however, the chronic use of anti-inflammatory drugs for these indications has been disappointing."	1.35	Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. ( Aiyar, N; Behm, DJ; Bentley, RG; Coatney, RW; Doe, CP; Eybye, ME; Maniscalco, K; Olzinski, AR; Westfall, TD; Willette, RN; Zhao, S, 2009)
"CHF was characterized by left ventricular remodeling and impaired systolic and diastolic function."	1.35	Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2008)
"Myocardial hypertrophy ventricular remodeling model was induced by abdominal aortic banding (AAB) in rats."	1.34	[Influnce of Tinglizi on some neuroendocrine factors and type I and III collagen in ventricular remodeling induced by abdominal aortic banding in rats]. ( Chen, CX; Guo, J, 2007)
"Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI."	1.33	Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005)
"The study was made in 45 patients with congestive heart failure treated in the Department of Cardiology."	1.32	[Cytokines and remodeling of the heart in patients with congestive heart failure]. ( Jołda-Mydłowska, B; Salomon, P, 2003)
"Aldosterone promotes collagen synthesis and structural remodeling of the heart."	1.32	Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. ( Colucci, WS; Kerstetter, DL; Ooi, H; Sam, F; Singh, K; Singh, M; Xie, Z, 2004)
"Enrasentan-treated groups exhibited significantly improved survival (90-95% vs."	1.31	Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. ( Aiyar, N; Anderson, KM; Barone, FC; Coatney, RW; Nelson, AH; Ohlstein, EH; Olzinski, AR; Willette, RN; Woods, T, 2001)

Research

Studies (134)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

B-Type Natriuretic Peptide

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.49)	18.2507
2000's	63 (47.01)	29.6817
2010's	55 (41.04)	24.3611
2020's	14 (10.45)	2.80

Authors	Studies
Cheng, CJ	1
Mandour, AS	1
Yoshida, T	1
Watari, T	1
Tanaka, R	1
Matsuura, K	1
Chang, Y	1
Ben, Y	1
Li, H	1
Xiong, Y	1
Chen, G	2
Hao, J	1
Ma, X	1
Gao, X	4
Qiang, P	1
Shimosawa, T	1
Wang, X	7
Yang, F	1
Xu, Q	1
Chen, UL	1
Liao, CW	3
Wang, SM	1
Lai, TS	1
Huang, KH	1
Chang, CC	2
Lee, BC	2
Lu, CC	1
Chang, YR	2
Chang, YY	4
Hung, CS	4
Chueh, JS	1
Wu, VC	3
Tsai, CH	3
Lin, YH	4
Monzo, L	1
Huttin, O	2
Ferreira, JP	1
Lamiral, Z	1
Bozec, E	1
Beaumont, M	2
Micard, E	1
Baudry, G	1
Marie, PY	2
Eschalier, R	1
Rossignol, P	2
Zannad, F	2
Girerd, N	2
Kmieć, P	1
Rosenkranz, S	1
Odenthal, M	1
Caglayan, E	1
Bobenko, AI	1
Heller, S	1
Schmitt, N	1
Cherdtrakulkiat, R	1
Lawung, R	1
Nabu, S	1
Tantimavanich, S	1
Sinthupoom, N	1
Prachayasittikul, S	1
Prachayasittikul, V	1
Zhang, B	1
Wu, C	1
Zhang, Z	2
Yan, K	1
Li, C	2
Li, Y	5
Li, L	3
Zheng, C	1
Xiao, Y	1
He, D	1
Zhao, F	1
Su, JF	1
Lun, SM	1
Hou, YJ	1
Duan, LJ	1
Wang, NC	1
Shen, FF	1
Zhang, YW	1
Gao, ZW	1
Li, J	5
Du, XJ	1
Zhou, FY	1
Yin, Z	1
Zhu, J	2
Yan, D	1
Lou, H	1
Yu, H	1
Feng, C	1
Wang, Z	1
Wang, Y	6
Hu, X	1
Li, Z	2
Shen, Y	1
Hu, D	1
Chen, H	1
Wu, X	1
Duan, Y	1
Zhi, D	1
Zou, M	2
Zhao, Z	1
Zhang, X	2
Yang, X	2
Zhang, J	2
Wang, H	2
Popović, KJ	1
Popović, DJ	1
Miljković, D	1
Lalošević, D	1
Čapo, I	1
Popović, JK	1
Liu, M	1
Song, H	2
Xing, Z	1
Lu, G	3
Chen, D	1
Valentini, AM	1
Di Pinto, F	1
Coletta, S	1
Guerra, V	1
Armentano, R	1
Caruso, ML	1
Gong, J	1
Wang, N	1
Bian, L	1
Wang, M	1
Ye, M	1
Wen, N	1
Fu, M	1
Fan, W	1
Meng, Y	2
Dong, G	1
Lin, XH	2
Liu, HH	1
Gao, DM	1
Cui, JF	1
Ren, ZG	1
Chen, RX	1
Önal, B	1
Özen, D	1
Demir, B	1
Akkan, AG	1
Özyazgan, S	1
Payette, G	1
Geoffroy, V	1
Martineau, C	1
Villemur, R	1
Jameel, T	1
Baig, M	1
Gazzaz, ZJ	1
Tashkandi, JM	1
Al Alhareth, NS	1
Khan, SA	1
Butt, NS	1
Wang, J	3
Geng, Y	1
Zhang, Y	5
Liu, J	2
Basit, A	1
Miao, T	1
Liu, W	1
Jiang, W	1
Yu, ZY	1
Wu, L	2
Qu, B	1
Sun, JX	1
Cai, AL	1
Xie, LM	1
Groeneveld, J	1
Ho, SL	1
Mackensen, A	1
Mohtadi, M	1
Laepple, T	1
Genovesi, S	1
Nava, E	1
Bartolucci, C	1
Severi, S	1
Vincenti, A	1
Contaldo, G	1
Bigatti, G	1
Ciurlino, D	1
Bertoli, SV	1
Slovak, JE	1
Hwang, JK	1
Rivera, SM	1
Villarino, NF	1
Li, S	3
Cao, G	1
Ling, M	1
Ji, J	1
Zhao, D	1
Sha, Y	1
Liang, C	2
Guo, Q	1
Zhou, C	1
Ma, Z	1
Xu, J	3
Wang, C	1
Zhao, W	3
Xia, X	1
Jiang, Y	1
Peng, J	1
Jia, Z	1
Li, F	2
Chen, X	4
Mo, J	1
Zhang, S	3
Li, X	2
Huang, T	1
Zhu, Q	1
Wang, S	1
Ge, RS	1
Fortunato, G	1
Lin, J	2
Agarwal, PK	1
Kohen, A	1
Singh, P	1
Cheatum, CM	1
Zhu, D	1
Hayman, A	1
Kebede, B	1
Stewart, I	1
Frew, R	1
Guo, X	1
Gong, Q	1
Borowiec, J	1
Han, S	1
Zhang, M	1
Willis, M	1
Kreouzis, T	1
Yu, K	1
Chirvony, VS	1
Sekerbayev, KS	1
Pérez-Del-Rey, D	1
Martínez-Pastor, JP	1
Palazon, F	1
Boix, PP	1
Taurbayev, TI	1
Sessolo, M	1
Bolink, HJ	1
Lu, M	1
Lan, Y	1
Xiao, J	3
Song, M	1
Chen, C	2
Huang, Q	1
Cao, Y	2
Ho, CT	1
Qi, B	1
Wang, Q	1
Zhang, W	2
Fang, L	1
Xie, CL	1
Chen, R	1
Yang, S	1
Xia, JM	1
Zhang, GY	1
Chen, CH	1
Yang, XW	1
Domenech-Ximenos, B	1
Garza, MS	1
Prat-González, S	1
Sepúlveda-Martínez, Á	1
Crispi, F	1
Perea, RJ	1
Garcia-Alvarez, A	1
Sitges, M	1
Kalumpha, M	1
Guyo, U	1
Zinyama, NP	1
Vakira, FM	1
Nyamunda, BC	1
Varga, M	1
Drácz, L	1
Kolbenheyer, E	1
Varga, F	1
Patai, ÁV	1
Solymosi, N	1
Patai, Á	1
Kiss, J	1
Gaál, V	1
Nyul, Z	1
Mosdósi, B	1
Valdez, M	1
Moosavi, L	1
Heidari, A	1
Novakovic-Agopian, T	1
Kornblith, E	1
Abrams, G	1
McQuaid, JR	1
Posecion, L	1
Burciaga, J	1
D'Esposito, M	1
Chen, AJW	1
Samy El Gendy, NM	1
Wesolowska, P	1
Georg, D	1
Lechner, W	1
Kazantsev, P	1
Bokulic, T	1
Tedgren, AC	1
Adolfsson, E	1
Campos, AM	1
Alves, VGL	1
Suming, L	1
Hao, W	1
Ekendahl, D	1
Koniarova, I	1
Bulski, W	1
Chelminski, K	1
Samper, JLA	1
Vinatha, SP	1
Rakshit, S	1
Siri, S	1
Tomsejm, M	1
Tenhunen, M	1
Povall, J	1
Kry, SF	1
Followill, DS	1
Thwaites, DI	1
Izewska, J	1
Kang, JH	1
Yoon, Y	1
Song, J	1
Van de Winckel, A	1
Gauthier, L	1
Chao, CT	1
Lee, YH	1
Li, CM	1
Han, DS	1
Huang, JW	1
Huang, KC	1
Ni, L	1
Güttinger, R	1
Triana, CA	1
Spingler, B	1
Baldridge, KK	1
Patzke, GR	1
Shen, X	1
Wang, B	2
Xie, S	1
Deng, W	1
Wu, D	1
Zhang, Q	1
Voskamp, BJ	1
Peelen, MJCS	1
Ravelli, ACJ	1
van der Lee, R	1
Mol, BWJ	1
Pajkrt, E	1
Ganzevoort, W	1
Kazemier, BM	1
Tibrewala, R	1
Bahroos, E	1
Mehrabian, H	1
Foreman, SC	1
Link, TM	1
Pedoia, V	1
Majumdar, S	1
Jablonski, CL	1
Leonard, C	1
Salo, P	1
Krawetz, RJ	1
Yoon, N	1
Hong, SN	1
Cho, JG	1
Jeong, HK	1
Lee, KH	1
Park, HW	1
Barman, S	1
Konai, MM	1
Samaddar, S	1
Haldar, J	1
Mohamed, HSH	1
Li, CF	1
Hu, ZY	1
Deng, Z	1
Chen, LH	1
Su, BL	1
Chu, K	1
Liu, YP	1
Li, YB	1
Zhang, H	1
Xu, C	1
Zou, Z	1
Wu, Z	1
Xia, Y	1
Zhao, P	1
Wang, HT	1
de Biase, S	1
Pellitteri, G	1
Gigli, GL	1
Valente, M	1
Garg, A	1
Foinquinos, A	1
Jung, M	1
Janssen-Peters, H	1
Biss, S	1
Bauersachs, J	2
Gupta, SK	1
Thum, T	1
Cao, W	1
Zhan, E	1
Dragasevic, N	1
Jakovljevic, V	1
Zivkovic, V	1
Draginic, N	1
Andjic, M	1
Bolevich, S	1
Jovic, S	1
Pan, CT	2
Chen, ZW	2
Hill, MA	1
Jaisser, F	2
Sowers, JR	2
Qi, Y	1
Wu, XM	2
Chen, YL	1
Lin, LC	1
Ke, B	1
Tan, X	1
Ren, L	1
Fan, Y	1
Sun, Q	1
Liu, T	1
Jia, L	1
Du, J	1
Bilchenko, О	1
Kravtsova, V	1
Samburh, Y	1
Hodlevska, O	1
Gavrilyuk, V	1
Chou, CH	1
Wei, LH	1
Chen, CW	1
Shun, CT	1
Wen, WF	1
Wan, CH	1
Wu, KD	1
de Paula Vasconcelos, PC	1
Tirloni, CAS	1
Palozi, RAC	1
Leitão, MM	1
Carneiro, MTS	1
Schaedler, MI	1
Silva, AO	1
Souza, RIC	1
Salvador, MJ	1
Junior, AG	1
Kassuya, CAL	1
Lother, A	1
Deng, L	1
Huck, M	1
Fürst, D	1
Kowalski, J	1
Esser, JS	1
Moser, M	1
Bode, C	1
Hein, L	1
Liu, GZ	1
Li, YY	1
Liu, YW	1
Zhao, XB	1
Yuan, Y	1
Zhang, JW	1
Khannanova, Z	1
Sztechman, D	1
Czarzasta, K	1
Cudnoch-Jedrzejewska, A	1
Szczepanska-Sadowska, E	1
Zera, T	1
Könemann, S	1
Sartori, LV	1
Gross, S	1
Hadlich, S	1
Kühn, JP	1
Samal, R	1
Bahls, M	1
Felix, SB	1
Wenzel, K	1
Preston, IR	1
Sagliani, KD	1
Warburton, RR	1
Hill, NS	1
Fanburg, BL	1
Jaffe, IZ	1
Yasuoka, S	1
Kai, H	1
Kajimoto, H	1
Kudo, H	1
Takayama, N	1
Anegawa, T	1
Koga, M	1
Miyamoto, T	1
Mifune, H	1
Kage, M	1
Hirooka, Y	1
Imaizumi, T	1
Yang, R	1
Liu, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Multiparametric Study of Cardiac Remodeling After Myocardial Infarction Revascularized in Acute Phase : Relation With the Serum Concentrations in Aldosterone[NCT01109225]		145 participants (Actual)	Interventional	2010-04-27	Completed
Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)[NCT00113087]	Phase 3	230 participants (Actual)	Interventional	2003-08-31	Completed
The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study[NCT00132093]	Phase 4	100 participants	Interventional	2005-04-30	Completed
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260]	Phase 3	496 participants (Actual)	Interventional	1995-06-30	Completed
Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial[NCT04508985]		46 participants (Actual)	Interventional	2020-10-01	Completed
Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure[NCT00403910]	Phase 3	500 participants	Interventional	2002-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

B-Type Natriuretic Peptide (BNP) level. (NCT00113087)
Timeframe: Measured just prior to the Glenn surgery

B-type Natriuretic Peptide Level

Intervention	pg/ml (Median)
Enalapril	79
Placebo	84

B-type natriuretic peptide (BNP) level. (NCT00113087)
Timeframe: at the time of the 14 month visit

Ejection Fraction (%)

Intervention	pg/ml (Median)
Enalapril	25
Placebo	39

Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction (%) is defined as percentage of stroke volume of a ventricle (i.e. the difference between end diastolic and end systolic volumes)relative to end diastolic volume. (NCT00113087)
Timeframe: at 14 months of age

Ejection Fraction (%)

Intervention	percent (of end diastolic volume) (Mean)
Enalapril	59.3
Placebo	57.9

Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction % is defined as the percentage of the stroke volume (i.e. difference between end-diastolic and end-systolic volumes) in a ventricle relative to end-diastolic volume. (NCT00113087)
Timeframe: just before the Glenn surgery

End Diastolic Volume Z-score

Intervention	percent (of end diastolic volume) (Mean)
Enalapril	57.9
Placebo	56.6

Two-dimensional echocardiography endpoint -total End diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

End-diastolic Volume

Intervention	standard deviation (Mean)
Enalapril	2.3
Placebo	2.1

Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age

End-diastolic Volume

Intervention	ml (Mean)
Enalapril	29.2
Placebo	30.7

Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

End-diastolic Volume Z-score

Intervention	ml (Mean)
Enalapril	24.1
Placebo	23.2

Two-dimensional echocardiography endpoint -total end-diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age

Head Circumference-for-age Z-score

Intervention	standard deviation (Mean)
Enalapril	1.1
Placebo	1.3

Head circumference-for-age z-score at 14 months of age.In primary analysis outcome is defined as predicted mean of Head circumference z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age

Height-for-age Z-score

Intervention	standard deviation (Least Squares Mean)
Enalapril	-0.55
Placebo	0.09

Height-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of height z-score at age 14 months based on longitudinal modeling (adjusted bor baseline value) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age

MacArthur-Bates Inventory -Phrases Understood

Intervention	standard deviation (Least Squares Mean)
Enalapril	-1.00
Placebo	-0.86

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Phrases Understood z-score. (NCT00113087)
Timeframe: at 14 months of age

MacArthur-Bates Inventory -Total Gestures

Intervention	standard deviation (Mean)
Enalapril	-0.48
Placebo	-0.92

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score. (NCT00113087)
Timeframe: at 14 months of age

MacArthur-Bates Inventory -Words Produced

Intervention	standard deviation (Mean)
Enalapril	-0.86
Placebo	-1.31

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Produced z-score. (NCT00113087)
Timeframe: at 14 months of age

MacArthur-Bates Inventory -Words Understood

Intervention	standard deviation (Median)
Enalapril	-0.60
Placebo	-0.63

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Understood z-score. (NCT00113087)
Timeframe: at 14 months of age

Neurodevelopmental Status (FSII)

Intervention	standard deviation (Mean)
Enalapril	-0.46
Placebo	-0.82

Functional status II (Revised) Total Score. Scale ranges up to 100.00, the higher the better. The score presents an instrument for assessing health status for children surviving long term with chronic physcial disorders. (NCT00113087)
Timeframe: at 14 months of age

Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score

Intervention	units on a scale (Median)
Enalapril	96.4
Placebo	96.4

"Neurodevelopmental status (PDI):~the Bayley Scales of Infant Development: Psychomotor Development index z-score ." (NCT00113087)
Timeframe: at 14 months of age

Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score

Intervention	standard deviation (Mean)
Enalapril	-1.29
Placebo	-1.32

Neurodevelopmental status(MDI):Bayley Scales of infant development, Mental Developmental Index z-score . (NCT00113087)
Timeframe: at 14 months of age

Number of Participants With Moderate to Severe AV Valve Regurgitation

Intervention	standard deviation (Mean)
Enalapril	-0.26
Placebo	-0.33

Number of participants with moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: at age 14 months

Number of Participants With Moderate to Severe AV Valve Regurgitation

Intervention	participants (Number)
Enalapril	11
Placebo	22

Number of participants with Moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: just before the pre-Glenn surgery

Number of Participants With Ross Heart Failure Class I

Intervention	participants (Number)
Enalapril	20
Placebo	32

Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise. (NCT00113087)
Timeframe: Just prior to the pre-Glenn surgery

Number of Participants With Ross Heart Failure Class I

Intervention	Participants (Number)
Enalapril	53
Placebo	56

Ventricular Filling Pressure

Intervention	participants (Number)
Enalapril	72
Placebo	77

Ventricular filling pressure measured by catherization (NCT00113087)
Timeframe: just before the Glenn surgery

Ventricular Mass

Intervention	mmHg (Mean)
Enalapril	10.9
Placebo	11.1

Two-dimensional echocardiography endpoint - Total Ventricular mass (g) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

Ventricular Mass

Intervention	g (Mean)
Enalapril	25.5
Placebo	28.1

Two-Dimensional Echocardiography endpoint-Total Ventricular mass (g) per Core Laboratory assessment. Range from 15.60 to 70.40 (NCT00113087)
Timeframe: At 14 months of age

Ventricular Mass to Volume Ratio

Intervention	g (Mean)
Enalapril	31.4
Placebo	34.4

Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured at 14 months of age

Ventricular Mass to Volume Ratio

Intervention	g/ml (Mean)
Enalapril	1.14
Placebo	1.20

Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured just before the Glenn surgery

Ventricular Mass Z-score

Intervention	g/ml (Mean)
Enalapril	1.15
Placebo	1.31

Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age

Ventricular Mass Z-score

Intervention	standard deviation (Mean)
Enalapril	2.5
Placebo	3.1

Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

Weight-for-age Z-score at 14 Months of Age

Intervention	standard deviation (Mean)
Enalapril	4.0
Placebo	4.9

Weight-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of weight z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age

Article	Year
Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227 Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P	2019
The role of aldosterone inhibitors in cardiac ischemia-reperfusion injury. Canadian journal of physiology and pharmacology, 2021, Volume: 99, Issue:1 Topics: Aldosterone; Animals; Cardiotonic Agents; Clinical Trials as Topic; Disease Models, Animal; Heart Ve	2021
Left ventricular remodeling and dysfunction in primary aldosteronism. Journal of human hypertension, 2021, Volume: 35, Issue:2 Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Hypertrophy, Left Ventricular; Ventricular Dy	2021
Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness. Cardiovascular research, 2022, 01-07, Volume: 118, Issue:1 Topics: Aldosterone; Coronary Circulation; Coronary Vessels; Endothelial Cells; Epithelial Sodium Channels;	2022
Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2018, Volume: 69, Issue:6 Topics: Aldosterone; Animals; Arteries; Cardiovascular Diseases; Cardiovascular System; Heart; Humans; Recep	2018
The renin-angiotensin-aldosterone system and heart failure. Cardiology clinics, 2014, Volume: 32, Issue:1 Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit	2014
Aldosterone and Left Ventricular Remodeling. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2015, Volume: 47, Issue:13 Topics: Aldosterone; Essential Hypertension; Heart Ventricles; Humans; Hyperaldosteronism; Hypertension; Ven	2015
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. Blood purification, 2016, Volume: 41, Issue:1-3 Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure,	2016
Blocking aldosterone in heart failure. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:5 Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure;	2009
Brain renin-angiotensin-aldosterone system and ventricular remodeling after myocardial infarct: a review. Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:12 Topics: Aldosterone; Animals; Apoptosis; Brain; Humans; Myocardial Infarction; Myocarditis; Myocytes, Cardia	2009
Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. Heart failure reviews, 2011, Volume: 16, Issue:1 Topics: Aldosterone; Animals; Disease Models, Animal; Fibrosis; Heart Failure; Humans; Hypercalciuria; Hyper	2011
Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation, 2011, Nov-01, Volume: 124, Issue:18 Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorti	2011
Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovascular drugs and therapy, 2013, Volume: 27, Issue:2 Topics: Aldosterone; Animals; Humans; Hyperaldosteronism; Parathyroid Hormone; Ventricular Remodeling	2013
Local cardiac renin-angiotensin system: hypertension and cardiac failure. Journal of molecular and cellular cardiology, 2002, Volume: 34, Issue:11 Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically	2002
Molecular mechanisms of myocardial remodeling. The role of aldosterone. Journal of molecular and cellular cardiology, 2002, Volume: 34, Issue:12 Topics: Aldosterone; Animals; Cardiomyopathies; Female; Fibrosis; Heart Failure; Humans; Mice; Mice, Transge	2002
Heart failure: pathophysiologic mechanisms. The American journal of nursing, 2001, Volume: 101, Issue:12 Topics: Activities of Daily Living; Aldosterone; Apoptosis; Catecholamines; Cytokines; Diastole; Heart Failu	2001
Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Current drug targets, 2003, Volume: 4, Issue:6 Topics: Aldosterone; Animals; Biomarkers; Coronary Circulation; Fibrosis; Heart Failure; Humans; Hyperaldost	2003
Neurohormone activation. Critical care nursing clinics of North America, 2003, Volume: 15, Issue:4 Topics: Aldosterone; Disease Progression; Heart Failure; Humans; Natriuretic Peptides; Neurotransmitter Agen	2003
Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects. Molecular and cellular endocrinology, 2004, Mar-31, Volume: 217, Issue:1-2 Topics: Aldosterone; Animals; Coronary Disease; Cytochrome P-450 CYP11B2; Female; Gene Expression Regulation	2004
Aldosterone target organ protection by eplerenone. Molecular and cellular endocrinology, 2004, Mar-31, Volume: 217, Issue:1-2 Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hype	2004
Aldosterone and cardiovascular remodelling: focus on myocardial failure. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2004, Volume: 5, Issue:1 Topics: Aldosterone; Animals; Blood Vessels; Cardiac Output, Low; Cardiovascular System; Cytochrome P-450 CY	2004
The clinical implications of aldosterone escape in congestive heart failure. European journal of heart failure, 2004, Volume: 6, Issue:5 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular	2004
Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. International journal of cardiology, 2004, Volume: 96, Issue:3 Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; R	2004
Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. Current medicinal chemistry. Cardiovascular and hematological agents, 2004, Volume: 2, Issue:4 Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Ischemia; Myo	2004
[Aldosterone antagonist therapy for chronic heart failure]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Feb-10, Volume: 94, Issue:2 Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure	2005
[Left ventricular remodeling post myocardial infarction]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 3 Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Proco	2005
Pathophysiology of heart failure following myocardial infarction. Heart (British Cardiac Society), 2005, Volume: 91 Suppl 2 Topics: Aldosterone; Angiotensins; Fibrosis; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardia	2005
Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. The American journal of cardiology, 2006, May-22, Volume: 97, Issue:10A Topics: Aldosterone; Animals; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Ventric	2006
[Cardioprotective effect of aldosterone antagonists for ventricular remodeling]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 5 Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid	2006
Natriuretic peptides and remodeling in heart failure. Heart failure clinics, 2005, Volume: 1, Issue:1 Topics: Aldosterone; Animals; Cardiotonic Agents; Disease Progression; Dose-Response Relationship, Drug; End	2005
Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Annals of medicine, 1998, Volume: 30 Suppl 1 Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Endomyocardial Fibro	1998
Cardiac aldosterone production and ventricular remodeling. Kidney international, 2000, Volume: 57, Issue:4 Topics: Aldosterone; Animals; Fibrosis; Humans; Myocardial Infarction; Myocardium; Ventricular Remodeling	2000

Article	Year
Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction. International heart journal, 2014, Volume: 55, Issue:1 Topics: Aged; Aldosterone; Amides; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme In	2014
Usefulness of Speckle-Tracking Imaging for Right Ventricular Assessment after Acute Myocardial Infarction: A Magnetic Resonance Imaging/Echocardiographic Comparison within the Relation between Aldosterone and Cardiac Remodeling after Myocardial Infarction Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2015, Volume: 28, Issue:7 Topics: Aldosterone; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Humans; Magnetic Reso	2015
Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2016, Jun-20, Volume: 22, Issue:3 Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents;	2016
Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. Circulation, 2011, May-31, Volume: 123, Issue:21 Topics: Aldosterone; Angiotensins; Cohort Studies; Double-Blind Method; Female; Genotype; Growth Disorders;	2011
Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. European heart journal, 2012, Volume: 33, Issue:2 Topics: Aged; Aged, 80 and over; Aldosterone; Analysis of Variance; Cohort Studies; Echocardiography; Female	2012
Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. European journal of heart failure, 2011, Volume: 13, Issue:12 Topics: Aldosterone; Biomarkers; Double-Blind Method; Echocardiography; Electrocardiography; Eplerenone; Fem	2011
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:8 Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl	2006
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADK Kardiologiia, 2006, Volume: 46, Issue:7 Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting E	2006
Efficacy of low-dose continuous infusion of alpha-human atrial natriuretic peptide (hANP) during cardiac surgery: possibility of postoperative left ventricular remodeling effect. Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:11 Topics: Aged; Aldosterone; Arrhythmias, Cardiac; Atrial Natriuretic Factor; Blood Pressure; Cardiopulmonary	2006
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of cardiovascular medicine (Hagerstown, Md.), 2007, Volume: 8, Issue:9 Topics: Aged; Aldosterone; Biomarkers; Canrenone; Disease Progression; Double-Blind Method; Echocardiography	2007
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Journal of the American College of Cardiology, 2001, Volume: 37, Issue:5 Topics: Aged; Aldosterone; Cardiac Volume; Endomyocardial Fibrosis; Female; Follow-Up Studies; Heart Failure	2001

Article	Year
Changes in renin-angiotensin-aldosterone system during cardiac remodeling after mitral valvuloplasty in dogs. Journal of veterinary internal medicine, 2022, Volume: 36, Issue:2 Topics: Aldosterone; Animals; Cohort Studies; Dog Diseases; Dogs; Humans; Mitral Valve; Renin-Angiotensin Sy	2022
Eplerenone Prevents Cardiac Fibrosis by Inhibiting Angiogenesis in Unilateral Urinary Obstruction Rats. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2022, Volume: 2022 Topics: Actins; Aldosterone; Animals; Collagen; Eosine Yellowish-(YS); Eplerenone; Fibrosis; Glucocorticoids	2022
Diabetes mellitus is associated with more adverse non-hemodynamic left ventricular remodeling and less recovery in patients with primary aldosteronism. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2023, Volume: 71, Issue:2 Topics: Aldosterone; Diabetes Mellitus; Echocardiography; Humans; Hyperaldosteronism; Hypertension; Hypertro	2023
Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study. European journal of heart failure, 2023, Volume: 25, Issue:10 Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Strok	2023
Differential Role of Aldosterone and Transforming Growth Factor Beta-1 in Cardiac Remodeling. International journal of molecular sciences, 2023, Jul-31, Volume: 24, Issue:15 Topics: Aldosterone; Animals; Cardiomegaly; Eplerenone; Fibrosis; Male; Mice; Mice, Transgenic; Myocytes, Ca	2023
MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling. European journal of heart failure, 2020, Volume: 22, Issue:8 Topics: Aldosterone; Animals; Heart Failure; Mice; MicroRNAs; Mineralocorticoids; Receptors, Mineralocortico	2020
TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling. Clinical science (London, England : 1979), 2020, 06-26, Volume: 134, Issue:12 Topics: Adaptor Proteins, Vesicular Transport; Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Fibrosi	2020
Intradialytic hypotension and cardiac remodeling: should we consider the renin-angiotensin-aldosterone system? Renal failure, 2021, Volume: 43, Issue:1 Topics: Aldosterone; Humans; Hypotension; Renin-Angiotensin System; Ventricular Remodeling	2021
Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism. Frontiers in endocrinology, 2021, Volume: 12 Topics: Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Blood Pressure; Echocardiography; Essenti	2021
Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction. Science China. Life sciences, 2022, Volume: 65, Issue:3 Topics: Aged; Aldosterone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Pe	2022
PECULIARITIES OF REMODELING OF HEART AND NEUROHUMORAL STATUS IN PATIENTS WITH CHRONIC HEART FAILURE AND CONCOMITANT RENAL DISEASE DEPENDING ON THE VALUE OF THE EJECTION FRACTION OF THE LEFT VENTRICLE. Georgian medical news, 2017, Issue:270 Topics: Aldosterone; Chronic Disease; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocar	2017
IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovascular research, 2018, 04-01, Volume: 114, Issue:5 Topics: Adult; Aldosterone; Animals; Cardiomegaly; Case-Control Studies; Cells, Cultured; Collagen; Cytokine	2018
Diuretic herb Gomphrena celosioides Mart. (Amaranthaceae) promotes sustained arterial pressure reduction and protection from cardiac remodeling on rats with renovascular hypertension. Journal of ethnopharmacology, 2018, Oct-05, Volume: 224 Topics: Aldosterone; Amaranthaceae; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Diuretic	2018
Endothelial cell mineralocorticoid receptors oppose VEGF-induced gene expression and angiogenesis. The Journal of endocrinology, 2019, 01-01, Volume: 240, Issue:1 Topics: Aldosterone; Animals; Aorta; Cells, Cultured; Desoxycorticosterone Acetate; Disease Models, Animal;	2019
Aldosterone stimulation mediates cardiac metabolism remodeling via Sirt1/AMPK signaling in canine model. Naunyn-Schmiedeberg's archives of pharmacology, 2019, Volume: 392, Issue:7 Topics: Aldosterone; AMP-Activated Protein Kinases; Animals; Apoptosis; Dogs; Electrocardiography; Heart Ven	2019
Cardioprotective effect of the secretome of Sca-1+ and Sca-1- cells in heart failure: not equal, but equally important? Cardiovascular research, 2020, 03-01, Volume: 116, Issue:3 Topics: Aldosterone; Animals; Ataxin-1; Cells, Cultured; Disease Models, Animal; Female; Fibrosis; Galectin	2020
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. American journal of physiology. Lung cellular and molecular physiology, 2013, May-15, Volume: 304, Issue:10 Topics: Aldosterone; Animals; Arterial Pressure; Body Weight; Cardiac Output; Cell Proliferation; Fibrosis;	2013
Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:6 Topics: Active Transport, Cell Nucleus; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; Ep	2013
[Effect of Rhodiola Sacra on left ventricular remodeling and its mechanism in spontaneously hypertensive rats]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2013, Volume: 44, Issue:2 Topics: Aldosterone; Angiotensin II; Animals; Drugs, Chinese Herbal; Hypertension; Male; Rats; Rats, Inbred	2013
Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:10 Topics: Adult; Aldosterone; Blood Pressure Monitoring, Ambulatory; Cross-Sectional Studies; Echocardiography	2013
Aldosterone blockade reduces mortality without changing cardiac remodeling in spontaneously hypertensive rats. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2013, Volume: 32, Issue:5 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Electrocardiography; Gene Expression Regulation; Hy	2013
Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension. American journal of hypertension, 2014, Volume: 27, Issue:6 Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Aut	2014
Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:5 Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Cells, Cultured; Conne	2014
KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. Journal of hypertension, 2014, Volume: 32, Issue:7 Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Aldosterone; Female; Follow-Up Studies; G Protein-	2014
Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2014, Volume: 47, Issue:8 Topics: Aldosterone; Animals; Cardiotonic Agents; Chronic Disease; Collagen; Cytochrome P-450 CYP11B2; Disea	2014
Beneficial effects of houttuynin on ventricular remodeling induced by coronary artery ligation in rats. European journal of pharmacology, 2014, Oct-05, Volume: 740 Topics: Aldehydes; Aldosterone; Angiotensin I; Angiotensin II; Animals; Catalase; Collagen; Coronary Vessels	2014
Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:3 Topics: Aldosterone; Angiotensin II; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Catheter Abl	2014
Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade. American journal of physiology. Regulatory, integrative and comparative physiology, 2014, Oct-01, Volume: 307, Issue:7 Topics: Aldosterone; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Eplerenone; Macrophages; Male; M	2014
Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors. Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:6 Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aldosterone; Angiotensin II Type 1 Receptor Blocke	2015
The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure. Neuropeptides, 2015, Volume: 51 Topics: Aldosterone; Animals; Arginine Vasopressin; Disease Models, Animal; Heart Failure; Male; Myocardium;	2015
Cardioprotective effect of polydatin on ventricular remodeling after myocardial infarction in coronary artery ligation rats. Planta medica, 2015, Volume: 81, Issue:7 Topics: Aldosterone; Animals; Antioxidants; Captopril; Collagen; Coronary Occlusion; Coronary Vessels; Endot	2015
Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension. American journal of hypertension, 2016, Volume: 29, Issue:2 Topics: Adult; Aldosterone; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertrophy, Left Ventric	2016
[Renal sympathetic denervation suppresses ventricular substrate remodeling in a canine high-rate pacing model]. Zhonghua yi xue za zhi, 2015, Mar-24, Volume: 95, Issue:11 Topics: Aldosterone; Angiotensin II; Animals; Cardiac Pacing, Artificial; Dogs; Enzyme-Linked Immunosorbent	2015
Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2. Cellular signalling, 2015, Volume: 27, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Aldosterone; Animals; Cell Movement; Cell Proliferation; Cells	2015
Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study. Circulation. Cardiovascular imaging, 2016, Volume: 9, Issue:6 Topics: Adult; Aged; Aldosterone; Biomarkers; Biomechanical Phenomena; Blood Pressure; Case-Control Studies;	2016
Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. International journal of cardiology, 2016, Nov-01, Volume: 222 Topics: Aldosterone; Animals; Aortic Valve Stenosis; Cardiomegaly; Electrocardiography; Male; Mineralocortic	2016
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovascular therapeutics, 2017, Volume: 35, Issue:2 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel	2017
Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Cardiovascular research, 2009, Feb-15, Volume: 81, Issue:3 Topics: Aldosterone; Animals; Cardiac Catheterization; Corticosterone; Cytochrome P-450 CYP11B2; Disease Mod	2009
Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation, 2008, Nov-25, Volume: 118, Issue:22 Topics: Aldosterone; Biomarkers; C-Reactive Protein; Cardiomegaly; Electrocardiography; Female; Fibrin; Hear	2008
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation, 2009, Jan-06, Volume: 119, Issue:1 Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Catecholamines; Chronic Disease; Dependovirus; Di	2009
Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. Journal of hypertension, 2009, Volume: 27, Issue:6 Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; C-Reactive Protein; Cardiovascular Disease	2009
Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:3 Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; C	2009
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure. European journal of pharmacology, 2009, Nov-25, Volume: 623, Issue:1-3 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, So	2009
Effects of polydatin on attenuating ventricular remodeling in isoproterenol-induced mouse and pressure-overload rat models. Fitoterapia, 2010, Volume: 81, Issue:7 Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Cardiovascular Agents; Colla	2010
Effect of sodium houttuyfonate on inhibiting ventricular remodeling induced by abdominal aortic banding in rats. Canadian journal of physiology and pharmacology, 2010, Volume: 88, Issue:7 Topics: Aldosterone; Alkanes; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Collagen; Constrict	2010
Aldosterone inhibition and cardiovascular protection: more important than it once appeared. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa	2010
[Effect of Chrysanthemum indicum on ventricular remodeling in rats]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2010, Volume: 33, Issue:7 Topics: Aldosterone; Angiotensin II; Animals; Chrysanthemum; Disease Models, Animal; Drugs, Chinese Herbal;	2010
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3 Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease	2011
New take on the role of angiotensin II in cardiac hypertrophy and fibrosis. Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:6 Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Inflammation; Mi	2011
Aldosterone induces electrical remodeling independent of hypertension. International journal of cardiology, 2013, Apr-05, Volume: 164, Issue:2 Topics: Aldosterone; Animals; Hypertension; Male; Rats; Rats, Wistar; Tachycardia, Ventricular; Ventricular	2013
A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. American journal of physiology. Heart and circulatory physiology, 2011, Volume: 301, Issue:6 Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen; Cytokines; Disease Models, Animal	2011
Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. BMC cardiovascular disorders, 2011, Dec-02, Volume: 11 Topics: Aldosterone; Animals; Cell Proliferation; Echocardiography; Heart Failure; Hypertension, Pulmonary;	2011
The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling. PloS one, 2012, Volume: 7, Issue:1 Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; ErbB Receptors; Heart; Male; Mice; Mice, Trans	2012
Interferon-γ ablation exacerbates myocardial hypertrophy in diastolic heart failure. American journal of physiology. Heart and circulatory physiology, 2012, Sep-01, Volume: 303, Issue:5 Topics: Aldosterone; Animals; Autophagy; Disease Models, Animal; Disease Progression; Fibrosis; Heart Failur	2012
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:11 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Cardiovascular Agents;	2012
Aldosterone is not involved in the ventricular remodeling process induced by tobacco smoke exposure. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2012, Volume: 30, Issue:5 Topics: Aldosterone; Animals; Cardiovascular Diseases; Dietary Supplements; Echocardiography; Male; Rats; Ra	2012
Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease. American journal of veterinary research, 2012, Volume: 73, Issue:11 Topics: Aldosterone; Animals; Creatinine; Dog Diseases; Dogs; Female; Male; Mitral Valve Prolapse; Peptide F	2012
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism: clinical and experimental, 2013, Volume: 62, Issue:6 Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cell Size; Dr	2013
Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. Journal of hypertension, 2002, Volume: 20, Issue:7 Topics: Adult; Aged; Aldosterone; Arteries; Echocardiography; Female; Heart Ventricles; Humans; Hypertension	2002
Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. American heart journal, 2002, Volume: 144, Issue:3 Topics: Aged; Aldosterone; Angiotensin II; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood Vess	2002
[Cytokines and remodeling of the heart in patients with congestive heart failure]. Polskie Archiwum Medycyny Wewnetrznej, 2003, Volume: 109, Issue:1 Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Cardiomyopathy, Dilated; Catecholam	2003
Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. American journal of hypertension, 2004, Volume: 17, Issue:2 Topics: Aldosterone; Animals; Apoptosis; Blood Pressure; Dilatation, Pathologic; Disease Models, Animal; Ech	2004
Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5 Topics: Aged; Aldosterone; Antihypertensive Agents; Body Mass Index; Cohort Studies; Cross-Sectional Studies	2004
Is the female heart more sensitive to aldosterone for early remodeling? Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Estr	2004
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:6 Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone	2004
Effects of differential blockade of the renin-angiotensin system in postinfarcted rats. Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:3 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim	2004
Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses. American journal of physiology. Heart and circulatory physiology, 2004, Volume: 286, Issue:6 Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Caspase 2; Caspase 3; Caspase 8; Ca	2004
Atrial remodeling in persistent atrial fibrillation: the potential role of aldosterone. European heart journal, 2004, Volume: 25, Issue:12 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Enalapril; Humans; Renin	2004
Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation, 2004, Jul-27, Volume: 110, Issue:4 Topics: Adrenomedullin; Aldosterone; Animals; Body Weight; Dinoprost; Disease Progression; Drug Evaluation,	2004
Cellular basis for therapeutic choices in heart failure. Circulation, 2004, Oct-26, Volume: 110, Issue:17 Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; A	2004
Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovascular research, 2004, Dec-01, Volume: 64, Issue:3 Topics: Administration, Oral; Aldosterone; Animals; Central Nervous System; Collagen; Epinephrine; Injection	2004
Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation, 2005, May-03, Volume: 111, Issue:17 Topics: Aldosterone; Animals; Cytochrome P-450 CYP11B2; Gene Expression Regulation; Male; Mice; Mice, Knocko	2005
Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Journal of molecular and cellular cardiology, 2005, Volume: 39, Issue:3 Topics: Aldosterone; Angiotensinogen; Animals; Animals, Genetically Modified; Brain; Cell Size; Fibronectins	2005
Aldosterone in heart failure: pathophysiology and treatment. Current heart failure reports, 2004, Volume: 1, Issue:4 Topics: Aldosterone; Death, Sudden, Cardiac; Endothelium, Vascular; Heart Failure; Humans; Hypertension; Min	2004
Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone. The international journal of biochemistry & cell biology, 2006, Volume: 38, Issue:3 Topics: Aldosterone; Animals; Body Weight; Collagen Type I; Glycoproteins; Heart; In Situ Hybridization; Int	2006
ANG II-induced cardiac molecular and cellular events: role of aldosterone. American journal of physiology. Heart and circulatory physiology, 2006, Volume: 291, Issue:1 Topics: Aldosterone; Angiotensin II; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Inflammatio	2006
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:4 Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Coronary Vessels; Corti	2006
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice. Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:9 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hy	2006
Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2006, Volume: 7, Issue:3 Topics: Aldosterone; Animals; Cardiotonic Agents; Chagas Cardiomyopathy; Collagen; Cricetinae; Disease Model	2006
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. Hypertension research : official journal of the Japanese Society of Hypertension, 2006, Volume: 29, Issue:8 Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis;	2006
Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology, 2007, Volume: 148, Issue:4 Topics: Aldosterone; Animals; Cell Line; Extracellular Matrix Proteins; Gene Expression Regulation; Genes, I	2007
Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertension research : official journal of the Japanese Society of Hypertension, 2006, Volume: 29, Issue:11 Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con	2006
Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:2 Topics: Aldosterone; Analysis of Variance; Animals; Cardiovascular Physiological Phenomena; Disease Models,	2007
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:3 Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate	2007
Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure. The American journal of cardiology, 2007, Jul-15, Volume: 100, Issue:2 Topics: Aldosterone; Alleles; Black or African American; Chronic Disease; Cytochrome P-450 CYP11B2; Echocard	2007
[Influnce of Tinglizi on some neuroendocrine factors and type I and III collagen in ventricular remodeling induced by abdominal aortic banding in rats]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2007, Volume: 30, Issue:8 Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Collagen; Constriction; Drug	2007
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochemical pharmacology, 2008, Mar-15, Volume: 75, Issue:6 Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines;	2008
[Role of cardiac aldosterone in post-infarction ventricular remodeling in rats]. Archives des maladies du coeur et des vaisseaux, 1999, Volume: 92, Issue:8 Topics: Aldosterone; Animals; Cytochrome P-450 CYP11B2; Myocardial Infarction; Rats; Reverse Transcriptase P	1999
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. Journal of cardiovascular pharmacology, 2001, Volume: 38, Issue:4 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Carboxylic Acids; Endothelin Recept	2001
Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. Journal of the American College of Cardiology, 2001, Nov-01, Volume: 38, Issue:5 Topics: Acute Disease; Aged; Aldosterone; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhi	2001
Left ventricular structure and diastolic function in subjects with two hypertensive parents. Blood pressure, 2001, Volume: 10, Issue:4 Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Blood Pressure; Case-Control Studies; Catecholamines	2001

aldosterone and Cardiac Remodeling, Ventricular

Research Excerpts

Research

Studies (134)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

B-Type Natriuretic Peptide

B-type Natriuretic Peptide Level

Ejection Fraction (%)

Ejection Fraction (%)

End Diastolic Volume Z-score

End-diastolic Volume

End-diastolic Volume

End-diastolic Volume Z-score

Head Circumference-for-age Z-score

Height-for-age Z-score

MacArthur-Bates Inventory -Phrases Understood

MacArthur-Bates Inventory -Total Gestures

MacArthur-Bates Inventory -Words Produced

MacArthur-Bates Inventory -Words Understood

Neurodevelopmental Status (FSII)

Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score

Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score

Number of Participants With Moderate to Severe AV Valve Regurgitation

Number of Participants With Moderate to Severe AV Valve Regurgitation

Number of Participants With Ross Heart Failure Class I

Number of Participants With Ross Heart Failure Class I

Ventricular Filling Pressure

Ventricular Mass

Ventricular Mass

Ventricular Mass to Volume Ratio

Ventricular Mass to Volume Ratio

Ventricular Mass Z-score

Ventricular Mass Z-score

Weight-for-age Z-score at 14 Months of Age

Reviews

Trials

Other Studies